Fragment-based lead discovery: Leads by design

Drug Discovery Today

Volumn 10, Issue 14, 2005, Pages 987-992

  Carr, Robin A E ^a   Congreve, Miles ^a   Murray, Christopher W ^a   Rees, David C ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETOHYDROXAMIC ACID; ADENOSINE TRIPHOSPHATE; BENZAMIDINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR; CYSTEINE PROTEINASE; DNA TOPOISOMERASE (ATP HYDROLYSING); HYDRAZINE; INDAZOLE DERIVATIVE; ISATIN; LIGAND; LY 517717; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSELTAMIVIR; PHENOL; PHOSPHODIESTERASE IV; STROMELYSIN; THIOL; UNCLASSIFIED DRUG; ZINC ION;

ATOM; BINDING AFFINITY; BIOASSAY; CHEMICAL STRUCTURE; COMBINATORIAL CHEMISTRY; CONCENTRATION (PARAMETERS); CRYSTALLOGRAPHY; DISULFIDE BOND; DRUG DESIGN; DRUG IDENTIFICATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG SCREENING; ENZYME ACTIVE SITE; FRAGMENT BASED LEAD DISCOVERY; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; PROTEIN STRUCTURE; REVIEW; SCREENING; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

DRUG DESIGN; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR WEIGHT; TECHNOLOGY, PHARMACEUTICAL;

EID: 22044441118     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03511-7     Document Type: Review

References (39)

1. J. Mestres, G.H. Veeneman Identification of "latent hits" in compound screening collections J. Med. Chem. 46 2003 3441 3444
2. P. Gribbon, S. Andreas High-throughput drug discovery: what can we expect from HTS? Drug Discov. Today 10 2005 17 22
3. M.M. Hann Molecular complexity and its impact on the probability of finding leads for drug discovery J. Chem. Inf. Comput. Sci. 41 2001 856 864
4. T.I. Oprea Is there a difference between leads and drugs? A historical perspective J. Chem. Inf. Comput. Sci. 41 2001 1308 1315
5. S.J. Teague The Design of Leadlike Combinatorial Libraries Angew. Chem. Int. Ed. Engl. 38 1999 3743 3748
6. D.A. Erlanson Fragment-based drug discovery J. Med. Chem. 47 2004 3463 3482
7. D.C. Rees Fragment-based lead discovery Nat. Rev. Drug Discov. 3 2004 660 672
8. C. Lipinski, A. Hopkins Navigating chemical space for biology and medicine Nature 432 2004 855 861
9. J. Seidler Identification and prediction of promiscuous aggregating inhibitors among known drugs J. Med. Chem. 46 2003 4477 4486
10. A.L. Hopkins Ligand efficiency: a useful metric for lead selection Drug Discov. Today 9 2004 430 431
11. I.D. Kuntz The maximal affinity of ligands Proc. Natl. Acad. Sci. U.S.A. 96 1999 9997 10002
12. M. Congreve A 'rule of three' for fragment-based lead discovery? Drug Discov. Today 8 2003 876 877
13. C.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 2001 3 26
14. N. Baurin Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets J. Chem. Inf. Comput. Sci. 44 2004 2157 2166
15. J. Fejzo The SHAPES strategy: an NMR-based approach for lead generation in drug discovery Chem. Biol. 6 1999 755 769
16. M.J. Hartshorn Fragment-based lead discovery using X-ray crystallography J. Med. Chem. 48 2005 403 413
17. H.J. Boehm Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promizing alternative to random screening J. Med. Chem. 43 2000 2664 2674
18. A.L. Gill Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation J. Med. Chem. 48 2005 414 426
19. J.W. Liebeschuetz PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors J. Med. Chem. 45 2002 1221 1232
20. G.L. Card A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design Nat. Biotechnol. 23 2005 201 207
21. S.B. Shuker Discovering high-affinity ligands for proteins: SAR by NMR Science 274 1996 1531 1534
22. D.A. Erlanson In situ assembly of enzyme inhibitors using extended tethering Nat. Biotechnol. 21 2003 308 314
23. M. Hochgurtel Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target J. Med. Chem. 46 2003 356 358
24. M. Hochgurtel Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries Proc. Natl. Acad. Sci. U.S.A. 99 2002 3382 3387
25. M.S. Congreve Detection of ligands from a dynamic combinatorial library by X-ray crystallography Angew. Chem. Int. Ed. Engl. 42 2003 4479 4482
26. P.J. Hajduk Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR J. Am. Chem. Soc. 119 1997 5818 5827
27. B.G. Szczepankiewicz Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy J. Am. Chem. Soc. 125 2003 4087 4096
28. M.C. Wenlock A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 46 2003 1250 1256
29. C.G. Wermuth Selective optimization of side activities: another way for drug discovery J. Med. Chem. 47 2004 1303 1314
30. P.J. Hajduk Druggability indices for protein targets derived from NMR-based screening data J. Med. Chem. 48 2005 2518 2525
31. D.J. Maly Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors Proc. Natl. Acad. Sci. U.S.A. 97 2000 2419 2424
32. S. Dickopf Custom chemical microarray production and affinity fingerprinting for the S1 pocket of factor VIIa Anal. Biochem. 335 2004 50 57
33. E.E. Swayze SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets J. Med. Chem. 45 2002 3816 3819
34. D.A. Ockey Structure-activity relationships by mass spectrometry: identification of novel MMP-3 inhibitors Bioorg. Med. Chem. 12 2004 37 44
35. D.A. Erlanson Tethering: fragment-based drug discovery Annu. Rev. Biophys. Biomol. Struct. 33 2004 199 223
36. C. Dalvit NMR-Based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of high-affinity ligands J. Med. Chem. 45 2002 2610 2614
37. W. Jahnke Spin label enhanced NMR screening J. Am. Chem. Soc. 123 2001 3149 3150
38. A. Ross Automation of NMR measurements and data evaluation for systematically screening interactions of small molecules with target proteins J. Biomol. NMR 16 2000 139 146
39. V.L. Nienaber Discovering novel ligands for macromolecules using X-ray crystallographic screening Nat. Biotechnol. 18 2000 1105 1108